The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report

Azziz, Ricardo; Carmina, Enrico; Dewailly, Didier; Diamanti-Kandarakis, Evanthia; Escobar-Morreale, Héctor F.; Futterweit, Walter; Janßen, Onno E.; Legro, Richard S.; Norman, Robert J.; Taylor, Ann E.; Witchel, Selma F.

doi:10.1016/j.fertnstert.2008.06.035

Cited by 1,727 publications

(1,266 citation statements)

References 311 publications

(385 reference statements)

Supporting

Mentioning

1,103

Contrasting

Unclassified

Order By: Relevance

“…The NIH criteria were strict and included only OA and HA [25]. The AES proposed that HA should be a mandatory criterion for the diagnosis, and the presence of either OA or PCOM is required because they are defined as two manifestations of ovarian dysfunction [24]. OA was defined as fewer than eight menstrual cycles during the previous 12 months or a menstrual interval of >35 days.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms

Şahmay

Aydın

Öncül

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose We assessed the utility of using anti-Müllerian hormone (AMH) and clinical features of polycystic ovary syndrome (PCOS), polycystic ovarian morphology (PCOM), oligo/amenorrhea (OA), and hyperandrogenism (HA) for diagnosing PCOS, and compared their diagnostic accuracy with those of classical diagnostic systems. Methods A total of 606 females were admitted to a university hospital with menstrual irregularities or symptoms of hyperandrogenism were enrolled in this cross-sectional study. Fasting blood samples were collected. Pelvic and/or abdominal ultrasonography and clinical examination were performed. Patients were evaluated for the presence of PCOS according to conventional diagnostic criteria. The diagnostic performance of using serum AMH levels alone and in various combinations with the clinical features of PCOM, OA, and HA were investigated. Results For the diagnosis of PCOS, the combination of OA and/or HA with AMH showed 83 % sensitivity and 100 % specificity according to the Rotterdam criteria; 83 % sensitivity and 89 % specificity according to the National Institutes of Health (NIH) criteria; and 82 % sensitivity and 93.5 % specificity according to the Androgen Excess Society (AES) criteria. Conclusions The serum AMH level is a useful diagnostic marker for PCOS and is correlated with conventional diagnostic criteria. The combination of AMH level with OA and/ or HA markedly increased the clinical scope for PCOS diagnosis and can be introduced as a possible objective criterion for the diagnosis of this disease.

show abstract

Section: Methodsmentioning

confidence: 99%

“…They all consider polycystic ovarian morphology (PCOM), oligo/ amenorrhea (OA), and hyperandrogenism (HA) [21][22][23][24][25]. However, each system has recently changed its definition of what constitutes a polycystic appearance [26,27].…”

Section: Introductionmentioning

confidence: 99%

Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms

Şahmay

Aydın

Öncül

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…It is a very heterogenous syndrome both in its clinical presentation and laboratory manifestations. The majority of women (75% to 100%) [4][5][6] with anovulation due to PCOS have menstrual irregularities, usually oligomenorrhea or amenorrhea, associated with clinical and/or biochemical evidence of hyperandrogenism. In addition to abnormal morphology of the ovary [7], increased ovarian production of androgens [8], hyperinsulinemia.…”

Section: Introductionmentioning

confidence: 99%

The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study

Ghandi

Aflatoonian

Tabibnejad

et al. 2011

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose Comparing the effects of metformin or orlistat on hormone, lipid profile and ovulation status in obese women with polycystic ovary syndrome. Methods A total of 80 women were prospectively recruited to receive either metformin (n=40) or orlistat (n=40). Weight, BMI, waist, serum LH, total serum testosterone and lipid profile were assessed at baseline and after 3 months. The subjects' ovulatory status was assessed after 3 months. Results There was no significant difference in ovulation between the two treatment groups (30% vs 15%). Treatment with either drug showed a significant decline in body weight, BMI (Body Mass Index), and waist circumference, but the degree of decline in both groups was the same. Patients who were treated with orlistat, showed a significant reduction in total testosterone and serum lipid. Women in metformin group showed a significant reduction in serum LH.Conclusions Both metformin and orlistat showed a similar effect on weight loss and ovulation rates.

show abstract

“…Согласно консенсусу ESHRE/ASRM (2003), верифици-ровать диагноз СПКЯ позволяет наличие по крайней мере двух из трёх следующих критериев: олиго-или ановуляция; клинические или биохимические при-знаки гиперандрогении, поликистозных яичников по данным ультразвукового исследования при ис-ключении других расстройств со сходной симптома-тикой (гиперпролактинемии, тиреоидной патологии, поздней формы адреногенитального синдрома, син-дрома гиперкортицизма) [15]. Благодаря расширению критериев диагностики, в настоящее время, наряду с «классическими», выделяют неполные («неклассиче-ские») фенотипы СПКЯ [2].…”

Section: Polycystic Ovary Syndrome (Pcos) Is the Most Common Endocrinunclassified

Endometrial Markers of Polycystic Ovary Syndrome (A Literature Review)

Sharifulin¹,

Шарифулин²,

Сутурина³

2018

Acta Biomedica Scientifica

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women and has a significant impact on various aspects of their health and the quality of life. The epidemiology of PCOS is well understood, while the prevalence of this syndrome depends on diagnostic criteria used, the characteristics of the population sample, and vary from 6-10 % to 15 % and higher. A number of studies suggest that the endometrium in women with PCOS differs from the normal endometrium morphologically and functionally. PCOS is associated with infertility problems, higher incidence of pregnancy complications and with increased risk of endometrial cancer, especially when obesity is present.

show abstract

The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report

Cited by 1,727 publications

References 311 publications

Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms

Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms

The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study

Endometrial Markers of Polycystic Ovary Syndrome (A Literature Review)

Contact Info

Product

Resources

About